Differences between Encofenib (Bitavi) and Canafenib and Analysis of Applicable Populations

Encorafenib (Encorafenib, also known as canafenib, trade name: Bitavid) is actually a different name for the same drug, so there is no essential difference in ingredients and mechanism of action. It is an oral small molecule BRAF inhibitor that targets tumors harboring BRAF V600 mutations. By inhibiting abnormally activated BRAF protein and blocking the Raf-MEK-ERK signaling pathway, it inhibits tumor cell proliferation and survival. Whether it is called encofenib or canafenib, its therapeutic mechanism and clinical use are consistent.

This drug is mainly suitable for BRAF V600 mutation-positive melanoma patients, as well as some patients with metastatic colorectal cancer who carry this mutation. It is usually used in patients whose disease has progressed after prior treatment with other treatments, such as immunotherapy or chemotherapy. For patients with melanoma, encofenib can be used in combination with MEK inhibitors (such as bimetinib/Binimetinib) to improve efficacy and delay the emergence of drug resistance.

In terms of the applicable population, encofenib is suitable for adult tumor patients with BRAF V600 mutations. Genetic testing is required before use to confirm whether the tumor carries the BRAF V600 mutation. In addition, patients with liver and kidney dysfunction, heart disease, or other serious underlying diseases should be used with caution under the guidance of a doctor. It has not been well studied in children and pregnant women and is not recommended.

In general, encofenib and canafenib are just named differently and are essentially the same drug, suitable for the treatment of BRAF V600 mutation-related tumors. When using it, patients need to be guided by a professional doctor and develop an individualized medication plan based on genetic test results, tumor type and individual tolerance. At the same time, pay attention to monitoring potential side effects, such as rash, fatigue, hematological abnormalities and liver function abnormalities, etc., to ensure safe and effective treatment.

Reference materials:https://www.drugs.com/